Google
COAG — HEMAB THERAPEUTICS HOLDINGS, INC. COMMON STOCK (Healthcare >> Biotechnology)
COAG FAQ
What is COAG's ROE?
HEMAB THERAPEUTICS HOLDINGS, INC. COMMON STOCK reports a Return on Equity (ROE) of 19.13%.
What is COAG's dividend yield?
HEMAB THERAPEUTICS HOLDINGS, INC. COMMON STOCK offers a dividend yield of 0.00%.
What is COAG's Deepscope Quality Score?
Deepscope rates COAG's overall financial quality at 38 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy COAG?
Deepscope's AI Timing Score for COAG is 56 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does COAG belong to?
HEMAB THERAPEUTICS HOLDINGS, INC. COMMON STOCK is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 25.30
Price
-0.11
(-0.43%)
Day Change
|
|
|---|
COAG, the overall quality is not good ( Quality = 38) and the timing to buy is ...(Sign In to See)...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROA is relatively low.
Acceleration of ROE growth rate is below our criteria.
Negative growth of ROE in the last year.
ROE is decreasing significantly
ROA is too relatively low compare to ROE
Acceleration of ROA growth rate is below our criteria.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not good , financial health is not good , and ability to make profit is not good , ...
| Quality Factors |
|
41% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 74 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 25.30 |
| PBV / Sector |
-6.15 / 4.63
|
| Earning Per Share | -0.79 |
| PE / Sector |
N/A / 17.43
|
| PEG or PE/Growth / Sector |
N/A / 0.53
|
| Average 1M Daily Value |
4.42 M
GREAT
|
| Average 1W Daily Value |
4.33 M
GREAT
|
| Timing Factors |
|
42% |
| Financial Health |
|
37% |
| Ability to Make Profit |
|
37% |
| Return to Investors |
|
8% |
| Registration Details |
| Analyze Date | 2026-06-06 09:08:30 |
| Symbol | COAG |
| Name | HEMAB THERAPEUTICS HOLDINGS, INC. COMMON STOCK |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 46.71 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 1,222.28 / 8,857.28 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 101 Main Street, Cambridge, MA, United States, 02142
Phone: (617) 553-3952
Website: https://www.hemab.com
Employees: 59
Sector: Healthcare >> Biotechnology
Description: Hemab Therapeutics Holdings, Inc. operates as a clinical-stage biotechnology company developing therapies that reimagine the treatment of blood coagulation disorders to sustain life and human resilience in United States of America and Denmark. Its products includes (HMB-001), is a bispecific antibody currently in Phase 1/2 clinical development for the prophylactic treatment of Glanzmann thrombasthenia and Phase 2 clinical development for the prophylactic treatment of Factor VII deficiency; and second clinical-stage asset, HMB-002, is a monovalent antibody in Phase 1/2 clinical development for the subcutaneous prophylactic treatment of Von Willebrand disease. It also advances multiple preclinical and discovery-stage assets. The company was founded in 2020 and is based in Cambridge, Massachusetts.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
